327 related articles for article (PubMed ID: 31806768)
1. Comparison Between
Rossi G; Bauckneht M; Genova C; Rijavec E; Biello F; Mennella S; Dal Bello MG; Cittadini G; Bruzzi P; Piva R; Ceriani V; Sambuceti G; Lopci E; Morbelli S; Grossi F
J Nucl Med; 2020 Jul; 61(7):990-998. PubMed ID: 31806768
[TBL] [Abstract][Full Text] [Related]
2. The utility of
Kitajima K; Kawanaka Y; Komoto H; Minami T; Yokoi T; Kuribayashi K; Kijima T; Nakamura A; Hashimoto M; Kondo N; Hasegawa S; Yamakado K
Hell J Nucl Med; 2021; 24(3):186-198. PubMed ID: 34901959
[TBL] [Abstract][Full Text] [Related]
3. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
[TBL] [Abstract][Full Text] [Related]
4. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
Shang J; Ling X; Zhang L; Tang Y; Xiao Z; Cheng Y; Guo B; Gong J; Huang L; Xu H
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466
[TBL] [Abstract][Full Text] [Related]
5. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using
Kitajima K; Watabe T; Nakajo M; Ishibashi M; Daisaki H; Soeda F; Tanemura A; Kanekura T; Yamazaki N; Ito K
Jpn J Radiol; 2022 Jan; 40(1):75-85. PubMed ID: 34287739
[TBL] [Abstract][Full Text] [Related]
6. Total metabolic tumor volume on
Tricarico P; Chardin D; Martin N; Contu S; Hugonnet F; Otto J; Humbert O
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38649279
[TBL] [Abstract][Full Text] [Related]
7. What
Turgeon GA; Iravani A; Akhurst T; Beaulieu A; Callahan JW; Bressel M; Cole AJ; Everitt SJ; Siva S; Hicks RJ; Ball DL; Mac Manus MP
J Nucl Med; 2019 Mar; 60(3):328-334. PubMed ID: 30030343
[TBL] [Abstract][Full Text] [Related]
8. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
9. Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non-Small Cell Lung Cancer.
Beer L; Hochmair M; Haug AR; Schwabel B; Kifjak D; Wadsak W; Fuereder T; Fabikan H; Fazekas A; Schwab S; Mayerhoefer ME; Herold C; Prosch H
Clin Nucl Med; 2019 Jul; 44(7):535-543. PubMed ID: 31021918
[TBL] [Abstract][Full Text] [Related]
10.
Humbert O; Cadour N; Paquet M; Schiappa R; Poudenx M; Chardin D; Borchiellini D; Benisvy D; Ouvrier MJ; Zwarthoed C; Schiazza A; Ilie M; Ghalloussi H; Koulibaly PM; Darcourt J; Otto J
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1158-1167. PubMed ID: 31760467
[TBL] [Abstract][Full Text] [Related]
11. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
Skougaard K; Nielsen D; Jensen BV; Hendel HW
J Nucl Med; 2013 Jul; 54(7):1026-31. PubMed ID: 23572497
[TBL] [Abstract][Full Text] [Related]
12. Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.
Bhoil A; Singh B; Singh N; Kashyap R; Watts A; Sarika S; Mittal BR
Hell J Nucl Med; 2014; 17(2):90-6. PubMed ID: 24997081
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of response to stereotactic body radiation therapy for nonsmall cell lung cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors.
Han J; Song Q; Guo F; Du R; Fang H; Kang J; Lu Z
Nucl Med Commun; 2022 Jun; 43(6):717-724. PubMed ID: 35354781
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of integrated
Umeda Y; Morikawa M; Anzai M; Ameshima S; Kadowaki M; Waseda Y; Shigemi H; Tsujikawa T; Kiyono Y; Okazawa H; Ishizuka T
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32345624
[TBL] [Abstract][Full Text] [Related]
15. Response Evaluation and Survival Prediction After PD-1 Immunotherapy in Patients with Non-Small Cell Lung Cancer: Comparison of Assessment Methods.
Ayati N; Lee ST; Zakavi SR; Cheng M; Lau WFE; Parakh S; Pathmaraj K; Scott AM
J Nucl Med; 2021 Jul; 62(7):926-933. PubMed ID: 33246978
[TBL] [Abstract][Full Text] [Related]
16. Response evaluation after immunotherapy in NSCLC: Early response assessment using FDG PET/CT.
Park S; Lee Y; Kim TS; Kim SK; Han JY
Medicine (Baltimore); 2020 Dec; 99(51):e23815. PubMed ID: 33371161
[TBL] [Abstract][Full Text] [Related]
17. Metabolic activity by
Kaira K; Higuchi T; Naruse I; Arisaka Y; Tokue A; Altan B; Suda S; Mogi A; Shimizu K; Sunaga N; Hisada T; Kitano S; Obinata H; Yokobori T; Mori K; Nishiyama M; Tsushima Y; Asao T
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):56-66. PubMed ID: 28828507
[TBL] [Abstract][Full Text] [Related]
18. Comparison of metabolic and anatomic response to chemotherapy based on PERCIST and RECIST in patients with advanced stage non-small cell lung cancer.
Ordu C; Selcuk NA; Akosman C; Eren OO; Altunok EC; Toklu T; Oyan B
Asian Pac J Cancer Prev; 2015; 16(1):321-6. PubMed ID: 25640373
[TBL] [Abstract][Full Text] [Related]
19. The lung cancers: staging and response, CT,
Owens C; Hindocha S; Lee R; Millard T; Sharma B
Br J Radiol; 2023 Aug; 96(1148):20220339. PubMed ID: 37097296
[TBL] [Abstract][Full Text] [Related]
20.
Fledelius J; Winther-Larsen A; Khalil AA; Bylov CM; Hjorthaug K; Bertelsen A; Frøkiær J; Meldgaard P
J Nucl Med; 2017 Dec; 58(12):1931-1937. PubMed ID: 28490472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
